- Patient characteristics (N=60).
| Characteristics | n (%) |
|---|---|
| Gender | |
| Male | 41 (68.3) |
| Female | 19 (31.7) |
| Histology | |
| Adenocarcinoma | 38 (63.3) |
| Squamous cell carcinoma | 14 (23.3) |
| Non-small cell lung cancer and poorly differentiated carcinoma | 5 (8.4) |
| Adenosquamous and neuroendocrine | 3 (5.0) |
| Stage | |
| I | 2 (3.3) |
| II | 7 (11.7) |
| III | 6 (10.0) |
| IV | 42 (70.0) |
| Missing | 3 (5.0) |
| EGFR status for stage IV and non-squamous NSCLC (n=30) | |
| Mutant | 7 (23.3) |
| Wild-type | 23 (76.7) |
| ALK for the cases who are stage IV and non-squamous NSCLC and wild EGFR (n=19) | |
| Mutant | 2 (10.5) |
| Wild-type | 17 (89.5) |
| ROS1 for the cases who are stage IV and non-squamous NSCLC and wild EGFR and ALK (n=15) | |
| Mutant | 1 (6.7) |
| Wild-type | 14 (93.3) |
| Survival status | |
| Dead | 30 (50.0) |
| Alive | 24 (40.0) |
| Lost to follow up | 6 (10.0) |
NSCLC: non-small cell lung carcinoma, ALK: anaplastic lymphoma kinase, EGFR: epidermal growth factor receptor, ROS1: c-ros oncogene 1